100 results
8-K
EX-99.1
COGT
Cogent Biosciences Inc
26 Feb 24
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
8:30am
systemic mastocytosis (NonAdvSM). Key highlights include:
oAnnounced the 100 mg Recommended Phase 2 Dose (RP2D)
oDemonstrated a well-tolerated safety … , a registration-directed trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM), include:
oReported an encouraging safety
8-K
COGT
Cogent Biosciences Inc
11 Dec 23
Other Events
8:04am
received prior avapritinib.
Safety Data
Bezuclastinib demonstrated an encouraging safety and tolerability profile for patients dosed at both 100 mg … a median duration of treatment in the open label extension (“OLE”) of 16 weeks. A consistent safety and tolerability profile was observed for patients
8-K
EX-99.1
d59of5ul9b5gkl1p526h
2 Nov 23
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
9:18am
8-K
EX-99.1
tmxrpoq3y
8 Aug 23
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
8:14am
8-K
EX-1.1
6b05n3ab 29o1qeuc5m
8 Jun 23
Entry into a Material Definitive Agreement
4:31pm
424B5
48ijjsz1ry0rg
8 Jun 23
Prospectus supplement for primary offering
4:01pm
424B5
l96yy1tc469djv
6 Jun 23
Prospectus supplement for primary offering
5:22pm
8-K
la9clpvd3sq 1bybtiq
6 Jun 23
Other Events
4:03pm
8-K
EX-99.1
emgzkjzmhaumen dq
9 May 23
Cogent Biosciences Reports Recent Business Highlights and First Quarter
8:13am
8-K
EX-99.2
cjm83s7e7rlhoob5qt
12 Dec 22
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating
8:03am
8-K
EX-99.1
1857fr6
12 Dec 22
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating
8:03am
8-K
EX-99.1
8w3 mwlluszt8tw
14 Nov 22
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results
7:14am